8-K 1 j7147_8k.htm 8-K

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC  20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

 

Date of Report (Date of earliest event reported): February 13, 2003

 

Array BioPharma Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

000-31979

 

84-1460811

(State or Other

 

(Commission

 

(IRS Employer

Jurisdiction of

 

File Number)

 

Identification No.)

Incorporation)

 

 

 

 

 

 

 

 

 

 

3200 Walnut Street, Boulder, Colorado

 

80301

(Address of Principal Executive Offices)

 

(Zip Code)

 

 

Registrant’s telephone number, including area code:    (303) 381-6600

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

 

ITEM 9.  REGULATION FD DISCLOSURE

 

The Registrant hereby furnishes, and attaches as Exhibits 99.1 and 99.2 hereto, the certifications required pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

2

 

 

SIGNATURES

                Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ARRAY BIOPHARMA INC.

 

 

 

Date:  February 13, 2003

By:

/s/ Robert E. Conway

 

 

Robert E. Conway

 

 

Chief Executive Officer

 

 

 

3

 

 

 

Exhibit No.

 

 

 

 

 

99.1

 

Written Certification of Robert E. Conway pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

99.2

 

Written Certification of R. Michael Carruthers pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

4